Not the same indications. One is plus remdesivir and one is versus placebo. And Chappell sales have been already stated to be pre-scheduled. I think you and Don are reading too much into this.
I think the EUA would end all placebo controlled trials at least in the US. A phase 4 trial would then start after the EUA is granted where there are no placebo patients. Since leronlimab's regular trial didn't have stat sig on mortality maybe they want a more robust ACTIV trial so that stat sig on mortality can be obtained.